Phaxiam Therapeutics Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest, by Didier Hoch, was filed 15 Oct 2024.
Phaxiam Therapeutics: what insiders have been doing
Phaxiam Therapeutics has a thin disclosure history in our data (latest filing: 15 October 2024). New filings will appear here as soon as they are published. These figures are compiled from regulatory filings published by AMF. They describe what insiders did and are not a recommendation.
- 22,052 shares@ €1.00100.0% of flowActionEuronext ParisISIN FR001400K4B12024DD1000137Canonical exit: 6 Jan 2025 (T+90)
- 22,052 shares0ActionEuronext ParisISIN FR001400K4B12024DD1000544
- 71,839 shares@ €0.61100.0% of flowActionHors plateforme de négociationISIN FR00114711352023DD918283
- 54,862 shares@ €0.61100.0% of flowActionHors plateforme de négociationISIN FR00114711352023DD917744
- 3,697,533 shares@ €0.6163.6% of flowActionHors plateforme de négociationISIN FR00114711352023DD917607
- 1,058,535 shares@ €0.6118.2% of flowActionHors plateforme de négociationISIN FR00114711352023DD900707
- 1,058,535 shares@ €0.6118.2% of flowActionHors plateforme de négociationISIN FR00114711352023DD900711
7 of 7 declarations
About Phaxiam Therapeutics
PHAXIAM THERAPEUTICS is a French biopharmaceutical company focused on the development of innovative treatments for severe and drug-resistant bacterial infections. Its scientific platform is built around phage therapy, a therapeutic approach that uses bacteriophages — naturally occurring viruses that kill specific bacteria — to address one of the most pressing public health challenges: antibiotic resistance. PHAXIAM has structured its portfolio around phages targeting three especially problematic hospital pathogens: Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, which its public communications indicate account for more than two-thirds of resistant hospital-acquired infections.
The company’s recent history reflects a strategic repositioning from Erytech into a pure-play phage therapy company. Headquartered in Lyon, France, PHAXIAM also maintained a presence in Cambridge, Massachusetts, giving it a transatlantic footprint that supports clinical development, scientific partnerships, and access to the broader biotech ecosystem. Throughout 2024, the company continued to advance its clinical and industrial roadmap while regularly updating the market on operational and financial progress.
Read moreShow less
Clinically, PHAXIAM has built much of its reputation around bone and joint infections, especially prosthetic joint infections (PJI), an area where it described itself as the most advanced phage-therapy player in Europe. The company has reported encouraging data from its clinical programs, including PhagoDAIR and the GLORIA Phase II program, which are intended to demonstrate the safety and efficacy of phages as an adjunct to standard-of-care treatment. In January 2025, PHAXIAM also announced a strategic collaboration with Technophage to develop individualized GMP phage therapies (IPT), broadening the industrial and therapeutic potential of its platform.
PHAXIAM is listed on Euronext Paris under ISIN FR001400K4B1 and ticker PHXM. The company raised financing in 2024 to support development efforts, and in June 2025 it announced the suspension of trading ahead of a delisting process. Based on the latest public information reviewed, PHAXIAM remains a specialized, high-innovation biotechnology company positioned in the fight against antimicrobial resistance.
